Nurix Therapeutics (NRIX) stock

Cancer medicines , market cap $1.6B

Cancer medicines

Worth $1.6B

$15.88

-1.61%

As of Tuesday's close · Live for Pro members at the open

Why is NRIX down?

Down 42% from Oct 28 to Nov 10.

Nurix Therapeutics fell 42% from Oct 28 to Nov 10. 36 points of it came on Nov 4.

Sources: Price history, Nov 10, 2026

−3News trial failure, analyst downgrade

Tell me next time NRIX moves

Free account, no card. An optional alert when NRIX moves or its score changes.

Or see it live, free until Thursday morning. No account.

1 more reason, free with an account →3 more reasons why NRIX fell 42% since Oct 28, from its filings, with the other side, how the business stands, the timeline, and its peers, for Pro members.

Why NRIX still beats the market over three years

Up 206% over the three years to Nov 9 while the S&P 500 rose 80%; down 42% since Oct 28.

1 reason, from its filings, with the timeline and its peers, for Pro members.

Quality Score

Below Average

In its industry

#131of 281

Biotech

Checks firing

1of 14

Trending up

From 52-week high

-43.7%

under its best in a year

NRIX's Quality Score was unchanged on Tue, Nov 10, at 1.

Follow NRIX's trial news. Pro members can get an alert when Nurix Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when NRIX files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Key facts on NRIX

Key facts on NRIX
The company	Sales up 739% on the year
Latest filing	8-K, Oct 13 Reported its quarterly results

1 more reason behind NRIX's 1, free with an account →2 more reasons behind NRIX's 1, for Pro members.

NRIX in the news

Wed Nov 4Sanofi discontinues Nurix drug trial, terminates program Investing.com and 4 more NRIX closed −38.2% that day.

Big story

Trial

Sanofi discontinues Nurix drug trial, terminates program

NRIX closed −38.2% the next session (Nov 4) on 9.8x normal volume.

Reported by Investing.com · covered by 5 outlets

Get an alert on NRIX's next big story →

What's next

Tue Nov 17: UBS Global Biopharma Conference 2026Investor conference · date confirmed.

3 more dates ahead: conferences, for Pro members.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

NRIX catalysts

Coming up

After its last 4 reports it closed -3.2% on average, higher 0 of 4 times.

6 past catalysts since 2021, with sizes and sources, for Pro members.

What's next for NRIX

Its trials

A trial underway: NX-5948 Versus Pirtobrutinib in R/R CLL/SLLPhase 3 · Recruiting · 620 people · main data estimated Oct 2029 · NCT07516093

5 more trials, 40 filings, for Pro members.

Dilution on the horizon

Shelf registration (S-3ASR, filed Jun 11, 2024)
At-the-market share sales program (S-3ASR, filed Jun 11, 2024)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

CFO Hans van Houte sold 4,769 shares on Nov 4, under a planned sale. 33 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Arthur Sands buys or sells

For Pro members: every trade, and Arthur Sands’s 2 filings and quotes.

Get an alert when NRIX files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

How NRIX ranks in Biotech

NRIX is #131 of 281 by Quality Score.

How NRIX ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	NGNENeurogene		Open for its score
	NKTRNektar Therapeutics		Open for its score
	NRXPNRX Pharmaceuticals		Open for its score
	NTLAIntellia Therapeutics		Open for its score
131	NRIXNurix Therapeutics	1/14	1

When does NRIX report earnings, and what happens after?

Expected to report Thu Jan 28, after the close (in 79 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What NRIX reported on Oct 13, 2026

The quarter

Sales of $673.1M; a profit of $4.73 a share, from a loss of $1.03.

“The increase was primarily due to $653.2 million of license revenue from the collaboration with Roche and $10.0 million from the achievement of a development milestone from the collaboration with Sanofi.”

The quarter that ended Aug 31, from the company's press release

The press release The filing on EDGAR

Where the sales came from

Where the quarter's sales came from
Line	Q3 FY26	Q3 FY25
By product
License Revenue	$653M97%	––

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Oct 13)

1 more line, for Pro members.

The outlook

No outlook figures read from this release.

In the company's words

“The decrease was primarily due to the cost sharing offset related to the collaboration with Roche.”

From its results filing (SEC filing · Oct 13)

1 more sentence, for Pro members.

The numbers

Market value: $1.6B; today
Sales: $702M; up 739% on the year
Free cash flow: $370M; last 12 months

Its share count grew 21% a year over 3 years.

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on NRIX: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-4.6%-6.6%-0.1%

Apr 8Jul 9Oct 13

Reported	When	Gap	Reaction	5 days
Oct 13, 2026Before open	Before open	0.0%	-0.1%	+12.5%
Jul 9, 2026After close	After close	+0.7%	-6.6%	-6.6%
Apr 8, 2026Before open	Before open	+1.4%	-4.6%	-0.3%

NRIX closed higher after 0 of its last 4 reports.

All 4 reports, and NRIX's Quality Score going into each

NRIX sales and profit by year

Sales and profit by year

Sales grew in two of the last three years, to $84M in 2025. It lost money in each of the four years.

NRIX has 1 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on NRIX, and all 14 on every stock.Get in free →

NRIX RSI today: 26.2, below its 50-day and 200-day averages

Not scored

RSI 26.2, MACD below signal, below both averages. Not scored.13 readings

The deep dive on NRIX

What it does and how it makes money3 findingsCollaboration Revenue made up 64% of its revenue in fiscal 2025 ($54.0M of $84.0M), against 100% in fiscal 2024; license revenue 36%.SEC filing · Jan 28, 2026
Where it stands1 findingFor Pro members1 finding on where NRIX stands: its cash, debt, and share count, for Pro members
What changed in its filings1 findingA new heading in its "Risk Factors" this year: "We may be exposed to foreign exchange risk." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Jan 28, 2026, against the one of Jan 28, 2025
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades NRIX, for Pro members

6 more findings on NRIX, each with its source, for Pro members.

NRIX share count over time

Shares: 32.6% more than a year ago (to Aug 31).

Shares of NRIX outstanding, as filed
Shares outstanding	As of
109.2M	Sep 30, 2026
103.8M	Jun 30, 2026
103.4M	Apr 1, 2026
102.8M	Jan 23, 2026

Offerings, shelves, and splits of NRIX, from its filings
From its filings	Filed
Raised $250M in a sale of shares, about 15% of its market value	Oct 22, 2025
Registered shares for a later sale (S-3ASR)	Jun 11, 2024
Raised $152.5M in a sale of shares, about 9% of its market value	Apr 12, 2024

NRIX insider trades

4 insiders sold $953K across 6 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellChristine Ring$104KChief Legal Officerat $26.28 on Oct 30, filed Nov 2

SellChristine RingChief Legal Officer$104Kat $26.28 on Oct 30, filed Nov 2

All 6 insider filings on NRIX from the last six months, for Pro members.

All NRIX insider trades

NRIX's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Hans van HouteChief Financial Officer · 8 trades
Christine RingChief Legal Officer · 20 trades
Gwenn HansenChief Scientific Officer · 10 trades
Julia P. GregoryDirector · 1 trade

See insider trades by person

Which ETFs hold NRIX?

In ETFs: NRIX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Nurix Therapeutics

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

357 employeesBrisbane, CAnurixtx.com

What Nurix Therapeutics says it competes with

“The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property and proprietary products.”

From its annual report, SEC filing · Jan 28, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on NRIX and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn NRIX's score around: 5 things
6 more filings explained, a plain line each
1 more thing pulling NRIX's score down

BreakawayNov 2Christine Ring sold NRIX$104K at $26.28, filed Nov 2

Alerts are optional.

See NRIX's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: NRIX's Quality Score is 1 (Below Average), #131 of 281 in Biotech. Insiders sold $953K in the last 6 months (Form 4).

What does NRIX's Quality Score say?

NRIX scores 1 today, which Breakaway calls Below Average. It is #131 of 281 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 42% from Oct 28 to Nov 10. Shares: 32.6% more than a year ago (to Aug 31). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is NRIX's Quality Score?

NRIX scores 1 today, which Breakaway calls Below Average (0 to 5). That is #131 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind NRIX's 1.

Are insiders buying NRIX?

4 insiders sold $953K across 6 filings in the last 6 months. No open-⁠market buys on record. The newest is Christine Ring, Chief Legal Officer, who sold $104K on Oct 30. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.